In partnership with

2025: The Year of the One-Card Wallet

When an entire team of financial analysts and credit card experts go to bat for the credit card they actually use, you should listen.

This card recommended by Motley Fool Money offers:

• 0% intro APR on purchases and balance transfers until nearly 2027

• Up to 5% cash back at places you actually shop

• A lucrative sign-up bonus

All for no annual fee. Don't wait to get the card Motley Fool Money (and everyone else) can't stop talking about.

Learn more --> 2025's "it" card

The HIMS Report

This newsletter outlines a stock analysis for Hims & Hers Health, Inc. (HIMS), a leading telehealth and wellness platform.

Fundamental Analysis

In its recent Q2 2025 earnings report, Hims & Hers delivered a stellar performance, with revenue surging 73% year-over-year to $544.8 million, and the company achieved a net income of $42.5 million. This growth was primarily driven by a 31% increase in its subscriber base, which now exceeds 2.4 million customers. The company's focus on new product lines, particularly its weight-loss offerings, is paying off and boosting revenue per subscriber. The company also affirmed its strong full-year 2025 revenue and Adjusted EBITDA guidance, signaling continued confidence in its business model.

Technical Analysis

Despite a recent dip following its earnings report, HIMS stock is in a dominant uptrend. The stock has risen significantly over the past year, outperforming both the healthcare industry and the broader market. The stock is currently trading in a rising trend channel and is on the verge of breaking through a key resistance level.

Big News

• Q2 2025 Earnings: The company's strong earnings and subscriber growth were the most significant news, demonstrating the success of its personalized care model.

• International Expansion: Hims & Hers announced plans to expand into Canada in 2026, following its recent acquisition of ZAVA Global to strengthen its European presence.

• Weight Loss Offerings: The company is seeing robust results from its weight loss plans, with data showing a 10.3% average body weight loss for subscribers on a personalized plan.

• Convertible Notes Offering: Hims & Hers successfully priced an upsized $870 million convertible senior notes offering to accelerate its global expansion and investment in AI.

Expert Recommendations and Forecast

The consensus among analysts for HIMS is a "Moderate Buy." While some analysts maintain a "Hold" or "Sell" rating, a significant portion recommends buying the stock. The average 12-month price target is approximately $46.33, which indicates a potential for upside from its current price.

Earnings and Outlook

Hims & Hers' next earnings report, for Q3 2025, is estimated to be on Monday, November 3, 2025. This report will be a key event for investors to see if the company's strong momentum can continue and if its strategic investments are driving further growth.